Author:
Karabeg Mia,Petrovski Goran,Hertzberg Silvia NW,Erke Maja Gran,Fosmark Dag Sigurd,Russell Greg,Moe Morten C.,Volke Vallo,Raudonis Vidas,Verkauskiene Rasa,Sokolovska Jelizaveta,Haugen Inga-Britt Kjellevold,Petrovski Beata Eva
Abstract
Abstract
Background
Diabetic retinopathy (DR) is the leading cause of adult blindness in the working age population worldwide, which can be prevented by early detection. Regular eye examinations are recommended and crucial for detecting sight-threatening DR. Use of artificial intelligence (AI) to lessen the burden on the healthcare system is needed.
Purpose
To perform a pilot cost-analysis study for detecting DR in a cohort of minority women with DM in Oslo, Norway, that have the highest prevalence of diabetes mellitus (DM) in the country, using both manual (ophthalmologist) and autonomous (AI) grading. This is the first study in Norway, as far as we know, that uses AI in DR- grading of retinal images.
Methods
On Minority Women’s Day, November 1, 2017, in Oslo, Norway, 33 patients (66 eyes) over 18 years of age diagnosed with DM (T1D and T2D) were screened. The Eidon - True Color Confocal Scanner (CenterVue, United States) was used for retinal imaging and graded for DR after screening had been completed, by an ophthalmologist and automatically, using EyeArt Automated DR Detection System, version 2.1.0 (EyeArt, EyeNuk, CA, USA). The gradings were based on the International Clinical Diabetic Retinopathy (ICDR) severity scale [1] detecting the presence or absence of referable DR. Cost-minimization analyses were performed for both grading methods.
Results
33 women (64 eyes) were eligible for the analysis. A very good inter-rater agreement was found: 0.98 (P < 0.01), between the human and AI-based EyeArt grading system for detecting DR. The prevalence of DR was 18.6% (95% CI: 11.4–25.8%), and the sensitivity and specificity were 100% (95% CI: 100–100% and 95% CI: 100–100%), respectively. The cost difference for AI screening compared to human screening was $143 lower per patient (cost-saving) in favour of AI.
Conclusion
Our results indicate that The EyeArt AI system is both a reliable, cost-saving, and useful tool for DR grading in clinical practice.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Cleland C. Comparing the International Clinical Diabetic Retinopathy (ICDR) severity scale. Community eye Health. 2023;36(119):10.
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet (British Edition). 2011;378(9785):31–40.
3. Saaddine JB, Honeycutt AA, Narayan KMV, Zhang X, Klein R, Boyle JP. Projection of Diabetic Retinopathy and other Major Eye diseases among people with diabetes Mellitus: United States, 2005–2050. Arch Ophthalmol. 2008;126(12):1740–7.
4. Stene LC, Ruiz PLD, Åsvold et al. How many people have diabetes in Norway in 2020? Tidsskr Nor Laegeforen. 2020.
5. Avogaro A, Fadini GP. Microvascular complications in diabetes: a growing concern for cardiologists. Int J Cardiol. 2019;291:29–35.